Systematic and quantitative analysis of stop codon readthrough in Rett syndrome nonsense mutations
Journal of Molecular Medicine · 2024
DOI: 10.1007/s00109-024-02436-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Medicine, 2024. Verfasst von Dennis Lebeda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department for Biochemistry and Molecular Medicine, Medical School EWL, Bielefeld University, Bielefeld, Germany. Hauptthemen laut MEDLINE: Codon, Nonsense, Rett Syndrome, Methyl-CpG-Binding Protein 2, Codon, Terminator. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, German-Israeli Foundation for Scientific Research and Development, Eva Luise und Horst Köhler Stiftung.
Abstract (Originalsprache)
Rett syndrome (RTT) is a neurodevelopmental disorder resulting from genetic mutations in the methyl CpG binding protein 2 ( MeCP2 ) gene. Specifically, around 35% of RTT patients harbor premature termination codons (PTCs) within the MeCP2 gene due to nonsense mutations. A promising therapeutic avenue for these individuals involves the use of aminoglycosides, which stimulate translational readthrough (TR) by causing stop codons to be interpreted as sense codons. However, the effectiveness of this treatment depends on several factors, including the type of stop codon and the surrounding nucleotides, collectively referred to as the stop codon context (SCC). Here, we develop a high-content reporter system to precisely measure TR efficiency at different SCCs, assess the recovery of the full-length MeCP2 protein, and evaluate its subcellular localization. We have conducted a comprehensive investigation into the intricate relationship between SCC characteristics and TR induction, examining a total of 14 pathogenic MeCP2 nonsense mutations with the aim to advance the prospects of personalized therapy for individuals with RTT. Our results demonstrate that TR induction can successfully restore full-length MeCP2 protein, albeit to varying degrees, contingent upon the SCC and the specific position of the PTC within the MeCP2 mRNA. TR induction can lead to the re-establishment of nuclear localization of MeCP2 , indicating the potential restoration of protein functionality. In summary, our findings underscore the significance of SCC-specific approaches in the development of tailored therapies for RTT. By unraveling the relationship between SCC and TR therapy, we pave the way for personalized, individualized treatment strategies that hold promise for improving the lives of individuals affected by this debilitating neurodevelopmental disorder. Key messages The efficiency of readthrough induction at MeCP2 premature termination codons strongly depends on the stop codon context. The position of the premature termination codon on the transcript influences the readthrough inducibility. A new high-content dual reporter assay facilitates the measurement and prediction of readthrough efficiency of specific nucleotide stop contexts. Readthrough induction results in the recovery of full-length MeCP2 and its re-localization to the nucleus. MeCP2 requires only one of its annotated nuclear localization signals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department for Biochemistry and Molecular Medicine, Medical School EWL, Bielefeld University, Bielefeld, Germany.
- Department of Child and Adolescent Health, University Medical Center Göttingen, Göttingen, Germany.
- Present Address: Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany.
- Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Department for Biochemistry and Molecular Medicine, Medical School EWL, Bielefeld University, Bielefeld, Germany. sven.thoms@uni-bielefeld.de.
- Department of Child and Adolescent Health, University Medical Center Göttingen, Göttingen, Germany. sven.thoms@uni-bielefeld.de.
ORCID-Profile: Dennis Lebeda, Sven Thoms
Förderung
- Deutsche Forschungsgemeinschaft
- German-Israeli Foundation for Scientific Research and Development
- Eva Luise und Horst Köhler Stiftung
- Universität Bielefeld
Zitieren
APA
Lebeda, D., Fierenz, A., Werfel, L., Rosin-Arbesfeld, R., Hofhuis, J., & Thoms, S. (2024). Systematic and quantitative analysis of stop codon readthrough in Rett syndrome nonsense mutations. Journal of Molecular Medicine. https://doi.org/10.1007/s00109-024-02436-6
Vancouver
Lebeda D, Fierenz A, Werfel L, Rosin-Arbesfeld R, Hofhuis J, Thoms S. Systematic and quantitative analysis of stop codon readthrough in Rett syndrome nonsense mutations. Journal of Molecular Medicine. 2024. doi:10.1007/s00109-024-02436-6
BibTeX
@article{Lebeda2024,
author = {Lebeda, Dennis and Fierenz, Adrian and Werfel, Lina and Rosin-Arbesfeld, Rina and Hofhuis, Julia and Thoms, Sven},
title = {Systematic and quantitative analysis of stop codon readthrough in Rett syndrome nonsense mutations},
journal = {Journal of Molecular Medicine},
year = {2024},
doi = {10.1007/s00109-024-02436-6}
}
EUVIMED